Monopar Therapeutics Inc. MNPR
71.78 USD -1.97 (-2.67%)
At closeNov 10, 2026, 4:00 PM EST
71.78 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
70.21 Day range 75.59
50.07 52-week range 124.82
- YTD
- +9.92%
- 1 year
- -13.60%
News
globenewswire.com Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026 WILMETTE, Ill., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
globenewswire.com Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
benzinga.com Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145 Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.
defenseworld.net Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast Regenicin (OTCMKTS:RGIN - Get Free Report) and Monopar Therapeutics (NASDAQ: MNPR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies…
globenewswire.com Monopar Appoints Jeffrey D. Kent, M.D. WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
seekingalpha.com Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy' Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 for Wilson disease and ongoing radiotherapeutic development. Completion of the rolling NDA for…
benzinga.com This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STUB downgraded, MNPR neutral, BETR.
benzinga.com Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128 Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.
benzinga.com Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119 Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.
247wallst.com Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is…- benzinga.com BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133 BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.
- benzinga.com Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.71 percent. This is a 77.14 percent decrease over losses…
globenewswire.com Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments…
benzinga.com HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $105 to $125.- benzinga.com Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections.…
globenewswire.com Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
globenewswire.com Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
seekingalpha.com Monopar Therapeutics: ALXN1840's Bull Case Has Improved Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN1840 for rare diseases. ALXN1840 is their Wilson disease asset, which currently has a much clearer…
benzinga.com Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson Disease Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced
globenewswire.com Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…- benzinga.com BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117 BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $104 to $117.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $105 price target.
benzinga.com Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN1840 At EAN 2026. Key findings presented at EAN 2026:In the subset of patients with neurologic symptoms at baseline from the 2:1 randomized Phase 3 FoCus clinical trial (NCT03403205; n=207), ALXN1840 demonstrated…
globenewswire.com Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
zacks.com Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
globenewswire.com Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
benzinga.com Monopar Therapeutics Publishes Phase 2 Study Demonstrating ALXN1840 Improves Copper Balance In Patients With Wilson Disease Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced
globenewswire.com Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for…
globenewswire.com Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for…
globenewswire.com Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 WILMETTE, Ill. , April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…- benzinga.com Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 72.65 percent increase over losses…
globenewswire.com Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative…
defenseworld.net Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC Ally Bridge Group NY LLC increased its position in shares of Monopar Therapeutics Inc. (NASDAQ: MNPR) by 86.6% in the undefined quarter, according to its most recent disclosure with the Securities…- benzinga.com BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.
- benzinga.com BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.
benzinga.com BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.- benzinga.com Morgan Stanley Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $115 Morgan Stanley analyst Maxwell Skor initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $115.
benzinga.com The Year-End 2025 Biotech Rally And What It Means For 2026 
benzinga.com This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - benzinga.com Raymond James Downgrades Monopar Therapeutics to Outperform, Lowers Price Target to $123 Raymond James analyst Chris Raymond downgrades Monopar Therapeutics (NASDAQ:MNPR) from Strong Buy to Outperform and lowers the price target from $142 to $123.
- benzinga.com Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $100 Price Target Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $100 price target.
- benzinga.com Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.45) by 7.38 percent. This is a 29.73 percent decrease over losses…
- benzinga.com Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $100 Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $85 to $100.
- benzinga.com Leerink Partners Initiates Coverage On Monopar Therapeutics with Outperform Rating, Announces Price Target of $115 Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Outperform rating and announces Price Target of $115.
benzinga.com This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125 Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $125.
- benzinga.com Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142 Raymond James analyst Chris Raymond maintains Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy and raises the price target from $80 to $142.
- benzinga.com Oppenheimer Maintains Outperform on Monopar Therapeutics, Raises Price Target to $115 Oppenheimer analyst Andreas Argyrides maintains Monopar Therapeutics (NASDAQ:MNPR) with a Outperform and raises the price target from $77 to $115.
- benzinga.com HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $70 to $105.